On January 5, 2026, the landscape of weight management in America shifted with the broad availability of Novo Nordisk's Wegovy® (semaglutide) pill. As the first and only FDA-approved oral GLP-1 receptor agonist for chronic weight management, it represents a monumental shift from injectable therapy, promising to expand access and transform patient experience. However, with...
A new international study protocol, published by the World Health Organization (WHO) in 2025, lays the groundwork for a critical public health initiative: determining how often a rare blood disorder occurs in children across low- and middle-income countries (LMICs). The study focuses on thrombocytopenia—a condition characterized by abnormally low platelet counts that can lead...
Nutrivigilance is the systematic monitoring, assessment, and prevention of adverse effects related to the use of food supplements, fortified foods, and other nutritional products. It is the pharmacovigilance equivalent for the nutraceutical and functional food sector.
This document is the "EDA Renal Anaemia Guidance to Good Pharmacy Practice" (Code: EDREX:GU.CAP.Care.016, Version: 2025), issued by the Egyptian Drug Authority's Central Administration of Pharmaceutical Care. It serves as a comprehensive, evidence-based clinical practice guideline for the management of anemia in patients with Chronic Kidney Disease (CKD).
The health-related SDGs are a subset of the United Nations’ 17 Sustainable Development Goals (2015–2030) that specifically focus on improving global health outcomes. They are tracked under SDG 3: “Ensure healthy lives and promote well-being for all at all ages”, but also include health-related indicators from other SDGs (e.g., clean water, nutrition, gender equality).
This is a master research protocol published by the World Health Organization (WHO) in 2025. Its primary purpose is to provide a standardized, ready-to-use blueprint for countries—particularly low- and middle-income countries (LMICs)
The UK Centre of Excellence for Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) has developed a landmark guideline on CYP2C19 genotype testing for clopidogrel, published in the British Journal of Clinical Pharmacology in 2025.
Advancing Medication Safety Through Knowledge and Vigilance
